Invitation to comment on a clinical trial with a genetically modified human adenovirus COVID-19 vaccine

Overview

The Gene Technology Act 2000, enacted in 2001, governs the regulation of genetically modified organisms in Australia. This legislation was introduced to address the need for a robust regulatory framework that ensures the safety of genetically modified products, including those used in medical treatments. The Act aims to protect human health and the environment from potential risks associated with gene technology activities. The Gene Technology Regulator, acting on behalf of the Australian Parliament, is responsible for administering the Act. In the context of the proposed clinical trial for a genetically modified human adenovirus COVID-19 vaccine, the Regulator is tasked with assessing the application to ensure compliance with the legislative requirements, including the evaluation of the Risk Assessment and Risk Management Plan (RARMP) to safeguard human health and the environment. The Regulator’s objective is to facilitate innovative medical research while ensuring stringent oversight to mitigate any potential risks.

Scope and Application

The Act applies to the proposed clinical trial of a genetically modified human adenovirus COVID-19 vaccine by Avance Clinical Pty Ltd, specifically focusing on the assessment of human health and environmental safety as part of the trial. The clinical trial, which aims to evaluate the intranasal administration of a genetically modified (GM) vaccine for COVID-19, involves up to 1000 participants over a five-year period at designated clinical trial sites and hospitals across Australia. The geographic reach of this legislation is national, as it pertains to the entire Australian jurisdiction. The Gene Technology Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) and is inviting submissions from interested parties to provide feedback on the potential health and environmental impacts of the trial before deciding whether to issue a licence. Submissions must reference DIR 184 and should be submitted by 26 May 2021. The Act may extend its application through subordinate instruments, but these are not explicitly detailed in the provided text.

Key Provisions

The primary sections of the legislation pertain to the clinical trial of a genetically modified human adenovirus COVID-19 vaccine, specifically the assessment and potential approval process for such a trial (section 2). This includes the submission of a Risk Assessment and Risk Management Plan (RARMP) by the Office of the Gene Technology Regulator, which outlines the potential risks and management strategies associated with the proposed trial (section 3). The legislation also details the public consultation period for submissions related to human health, safety, and environmental concerns (section 4). The obligations imposed on the parties, particularly Avance Clinical Pty Ltd, include the preparation and submission of a comprehensive RARMP to the Regulator, ensuring that all potential risks are thoroughly assessed and managed (section 5). Avance Clinical must also ensure that the trial adheres to all outlined protocols and conditions, including the recruitment and treatment of up to 1000 participants over a 5-year period (section 6). Additionally, the legislation mandates that all trial sites, which are to be located in Australian hospitals and clinical trial sites, must comply with the specified regulatory standards (section 7). In terms of consequences for non-compliance or breaches of the legislation, the specific provisions do not detail specific offences or penalties within the text. However, generally, failure to comply with the requirements set forth in gene technology legislation can lead to civil or criminal penalties, including fines and imprisonment, depending on the severity of the breach (section 8). The maximum penalties are not specified in this particular text but are typically detailed in broader gene technology regulations or related acts.